Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, England, Japan, Spain, China, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, hyper… Read more
Icares Medicus Inc (6612) - Net Assets
Latest net assets as of September 2025: NT$1.89 Billion TWD
Based on the latest financial reports, Icares Medicus Inc (6612) has net assets worth NT$1.89 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.14 Billion) and total liabilities (NT$1.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.89 Billion |
| % of Total Assets | 60.14% |
| Annual Growth Rate | 26.68% |
| 5-Year Change | 150.96% |
| 10-Year Change | N/A |
| Growth Volatility | 28.4 |
Icares Medicus Inc - Net Assets Trend (2017–2024)
This chart illustrates how Icares Medicus Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Icares Medicus Inc (2017–2024)
The table below shows the annual net assets of Icares Medicus Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.76 Billion | +5.63% |
| 2023-12-31 | NT$1.67 Billion | +77.96% |
| 2022-12-31 | NT$937.76 Million | +14.24% |
| 2021-12-31 | NT$820.90 Million | +16.87% |
| 2020-12-31 | NT$702.42 Million | +7.56% |
| 2019-12-31 | NT$653.04 Million | +14.28% |
| 2018-12-31 | NT$571.42 Million | +69.78% |
| 2017-12-31 | NT$336.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Icares Medicus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1298.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$436.79 Million | 26.31% |
| Other Components | NT$1.22 Billion | 73.69% |
| Total Equity | NT$1.66 Billion | 100.00% |
Icares Medicus Inc Competitors by Market Cap
The table below lists competitors of Icares Medicus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SCANA ASA NK 1
F:1MP
|
$46.71 Million |
|
ASICLAND
KQ:445090
|
$46.71 Million |
|
Ta-Yuan Cogeneration Co Ltd
TWO:8931
|
$46.73 Million |
|
6934
TWO:6934
|
$46.75 Million |
|
Hydratec Industries NV
AS:HYDRA
|
$46.69 Million |
|
Plotech Co Ltd
TW:6141
|
$46.69 Million |
|
Neontech Co. Ltd
KQ:306620
|
$46.69 Million |
|
Advanced Lithium Electrochemistry Cayman Co Ltd
TWO:5227
|
$46.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Icares Medicus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,577,962,000 to 1,660,032,000, a change of 82,070,000 (5.2%).
- Net income of 103,122,000 contributed positively to equity growth.
- Dividend payments of 7,832,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$103.12 Million | +6.21% |
| Dividends Paid | NT$7.83 Million | -0.47% |
| Other Changes | NT$-13.22 Million | -0.8% |
| Total Change | NT$- | 5.20% |
Book Value vs Market Value Analysis
This analysis compares Icares Medicus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.51x to 2.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$11.08 | NT$72.20 | x |
| 2018-12-31 | NT$17.16 | NT$72.20 | x |
| 2019-12-31 | NT$18.48 | NT$72.20 | x |
| 2020-12-31 | NT$19.54 | NT$72.20 | x |
| 2021-12-31 | NT$21.86 | NT$72.20 | x |
| 2022-12-31 | NT$25.51 | NT$72.20 | x |
| 2023-12-31 | NT$45.08 | NT$72.20 | x |
| 2024-12-31 | NT$35.03 | NT$72.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Icares Medicus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.21%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.99%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.81x
- Recent ROE (6.21%) is below the historical average (9.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 9.31% | 11.74% | 0.66x | 1.20x | NT$-2.32 Million |
| 2018 | 12.36% | 21.40% | 0.53x | 1.08x | NT$13.45 Million |
| 2019 | 12.99% | 19.32% | 0.53x | 1.27x | NT$18.67 Million |
| 2020 | 7.80% | 14.31% | 0.43x | 1.27x | NT$-14.68 Million |
| 2021 | 7.85% | 14.88% | 0.41x | 1.29x | NT$-16.08 Million |
| 2022 | 14.67% | 25.19% | 0.49x | 1.19x | NT$41.04 Million |
| 2023 | 6.19% | 16.14% | 0.32x | 1.21x | NT$-60.07 Million |
| 2024 | 6.21% | 11.99% | 0.29x | 1.81x | NT$-62.88 Million |
Industry Comparison
This section compares Icares Medicus Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,796,147,300
- Average return on equity (ROE) among peers: 10.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Icares Medicus Inc (6612) | NT$1.89 Billion | 9.31% | 0.66x | $46.70 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |